Researchers at George Mason University’s National Center for Biodefense and Infectious Diseases and its Center for Applied Proteomics and Molecular Medicine are merging their expertise in host-pathogen biology, proteomics and nanotechnology to discover tissue and bloodborne markers that could be used for the early detection of exposure to infectious diseases.